Trial Profile
A Prospective Observational Study in Patients With Wet Age-related Macular Degeneration or Diabetic Macular Edema to Assess the freQuency of Use of Intravitreal Aflibercept in Routine Clinical Practices in Latin America
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Jun 2021
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Diabetic macular oedema; Wet age-related macular degeneration
- Focus Therapeutic Use
- Acronyms AQUILA
- Sponsors Bayer
- 01 Feb 2021 Status changed from active, no longer recruiting to completed.
- 15 Dec 2020 Planned End Date changed from 8 Dec 2020 to 15 Jan 2021.
- 02 Nov 2020 Planned End Date changed from 6 Nov 2020 to 8 Dec 2020.